Dereck D Amakye MBChB DCH FFPM
Oncologist
Extensive pharmaceutical industry experience, with ~20 years in Oncology drug development, spanning translational medicine through late-stage development and life-cycle management.
Completed Medical Specialty Training in Pharmaceutical Medicine (Certified Specialist, UK) and Fellow of the Faculty of Pharmaceutical Medicine (FFPM) of Royal Colleges of Physicians. Currently, working as an independent Oncology Drug Development Consultant at DDA Consultancy LLC.
Summary of Experiences:
Zentalis Pharmaceuticals, Senior Vice-President
Clinical Development,- BayerPharmaceuticals, Vice-President ;
Head GMA Oncology Pipeline- Novartis
Institute of Biomedical Research, Global Clinical Program Leader - AstraZeneca
Oncology, UK, Global Brand Physician,
Clinical Development - AstraZeneca Oncology
Oncology Research Physician, Discovery Medicine- Covance Clinical Research Unit, UK Medical Director
Highlight Achievements:
• Investigator for ~ 300 phase 1 studies in healthy volunteers over a 6.5-year period at Covance CRU.
• Contributed to the development of many agents, which are now approved and marketed drugs, such as: Nplate (Amgen), for treating idiopathic thrombocytopenic purpura; Ramelteon (Takeda), for treating insomnia; Udenafil (Daichii), a
phosphodieterase 5 inhibitor, for erectile dysfunction; Exenatide (AstraZeneca) for diabetes mellitus; Tekturna (aliskiren, Novartis), a rennin antagonist, for treating hypertension; Tadalafil (Cialis, Lilly) for erectile dysfunction; Artemether-lumefantrine (Coartem, Novartis) for treating malaria; and Sonidegib (Odomzo, Sun Pharma [Novartis]) for the treatment of locally advance or recurrent BCC.
• Honorary Lecturer, University of Leeds (1998-2003) for Certificate in Clinical Research course.
Other team members
Oncologist/Pulmonologist
Dr. Giovanni Selvaggi is a US-based drug developer, cancer researcher, and strategic advisor to big pharma and early-to-late stage biotech companies with 14 years experience in industry and 17 in academia. Giovanni is currently Chief Medical Officer at Xcovery Holdings, where he manages an ongoing New Drug Application with the FDA for ensartinib, an ALK-TKI for non-small cell lung cancer. He is also a Clinical Consultant to Tubulis GmBH for a first-in-class ADC program in solid tumors; Clinical Strategy Senior VP to Alira Health, and advisor for CEL-SCI a first in class biotech that develops IO in head and neck oral cancer. He formerly served as Director/VP in multiple clinical development programs at GSK, Novartis (NDA with ceritinib), Oncolytics and BMS (NDA with Opdivo).
Dr. Selvaggi will be one of BusStim’s Oncology Evaluation team,
Neurologist
Rheumatologist
Leonard Sigal, MD is a Practicing rheumatologist and Independent consultant as Gateway Immunosciences, LLC. to the pharmaceutical-biotech industry and investment communities.
He has over 35 years of experience in rheumatology and basic & clinical immunology, Author of over 350 published medical and scientific articles & chapters, Winner of many teaching awards, clinical and pre-clinical education.
Dr. Sigal was previously Vice President, Global Therapeutic Area Leadership - Rheumatology & Immunology, PAREXEL. Before that position, he was Vice President - Medical & Science-Inflammation, NovoNordisk; Inaugural VP, immunosciences franchise, early Phase development of monoclonal antibodies in SLE, RA & IBD and Medical Director - Global Clinical Development, Bristol-Myers Squibb; led clinical development programs of abatacept in juvenile idiopathic arthritis, psoriatic arthritis and SLE. Earlier in his career, he was Chief, Division of Rheumatology, Professor in Departments of Medicine, Pediatrics, and Molecular Genetics & Microbiology, UMDNJ (now RUTGERS) -Robert Wood Johnson Medical School, New Brunswick, NJ.
He is a graduate of M.I.T. and Stanford Medical School. He did his internal medicine residency at Mt Sinai Medical Center in NYC and fellowships in rheumatology and clinical immunology at Yale. He is Board-Certified, Internal Medicine & Rheumatology and Board-eligible in Clinical Immunology
Oncologist
Extensive pharmaceutical industry experience, with ~20 years in Oncology drug development
